This Biotech Stock Surges on Rare Disease Drug Expectations Despite Insider Selling

Agios Pharmaceuticals Inc. (NASDAQ: AGIO) closed at $35.11 on April 7, up 0.89% from the previous trading day. Volume was about 1.35 million shares, and market capitalization stood at roughly $2.1 billion (around KRW 2.8 trillion), marking a one-day gain of about $18 million (approximately KRW 25 billion).

It was recently disclosed that Chief Financial Officer Cecilia Jones sold some 3,100 shares on April 2 at $34.71 per share, realizing approximately $109,000 (about KRW 150 million) in an insider transaction.

Agios is a biotech firm focused on developing oral enzyme modulators in the mitapivat class for rare hereditary hemolytic anemias and thalassemia, with PYRUKYND and AQVESME as its key growth pillars. The company is headquartered in Cambridge, Massachusetts.